Two separate studies examined the presence of a single nucleotide polymorphism (SNP) EGFR-K521 in different HNSCC clinical cohorts and found that while the SNP was not associated with the risk of cancer, it correlated with response to CTX treatment [30,80]. This evidence concerns the gene EGFR and cancer.